Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.
René J BoosmanCornedine J de GooijerStefanie L GroenlandJacobus A BurgersPaul BaasVincent van der NoortJos H BeijnenAlwin D R HuitemaNeeltje SteeghsPublished in: Pharmaceutical research (2022)
Pharmacokinetic exposure at a dose of 75 mg erlotinib when combined with the strong CYP3A4 inhibitor ritonavir is similar to 150 mg erlotinib. Ritonavir-boosting is a promising strategy to reduce erlotinib treatment costs and provides a rationale for other expensive therapies metabolized by CYP3A4.